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Abstract: Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA)
antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial
cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters
induces neutralising antibodies locally as well as systemically, affording partial protection against
Clostridioides difficile infection. The aim of this study was to determine whether displaying CD0873
on liposomes, mimicking native presentation, would drive a stronger antibody response. The
recombinant form we previously tested resembles the naturally cleaved lipoprotein commencing
with a cysteine but lacking lipid modification. A synthetic lipid (DHPPA-Mal) was designed for
conjugation of this protein via its N-terminal cysteine to the maleimide headgroup. DHPPA-Mal was
first formulated with liposomes to produce MalLipo; then, CD0873 was conjugated to headgroups
protruding from the outer envelope to generate CD0873-MalLipo. The immunogenicity of CD0873-
MalLipo was compared to CD0873 in hamsters. Intestinal sIgA and CD0873-specific serum IgG
were induced in all vaccinated animals; however, neutralising activity was greatest for the CD0873-
MalLipo group. Our data hold great promise for development of a novel oral vaccine platform
driving intestinal and systemic immune responses.
Keywords: oral vaccine; Clostridioides difficile; recombinant protein; sIgA; IgG; lipidation; liposomes
1. Introduction
Vaccination is the most effective medical intervention to prevent the spread of infec-
tious diseases [1]. However, with the rise in antimicrobial resistant infections, communica-
ble diseases are predicted to exceed cancer by 2050 and claim 10 million lives a year [2]
(WHO, 2019). Enteric infections alone cause more than a billion disease episodes annually
and claim nearly 2 million lives each year [3].
Most licensed vaccines are administered parenterally as intramuscular or subcuta-
neous injections. First-generation vaccines are composed of the whole organism, either live
attenuated or killed [4]. However, attenuated vaccines pose a safety risk, which limits their
use in the elderly or immunocompromised. Aside from the harmful pathogenic material
they contain, live vaccines can undergo spontaneous mutations and revert to their infec-
tious form, risking infecting the host [5,6]. To overcome this problem, efforts are focused on
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identifying individual antigens capable of safely eliciting immunoprotection [7]. However,
subunit vaccines are generally poorly immunogenic, necessitating co-administration with
immunostimulatory adjuvants [8,9]. A small number of adjuvants have been approved for
injected vaccines, including aluminium salts, monophosphoryl lipid A, squalene-based
oil-in-water emulsions and virosomes [10]. Of these adjuvants, alum salts are the most
widely used; however, their immunostimulatory activity can be weak, and formulations
containing alum cannot be stabilised by freeze-drying [11].
Intensive efforts have focused on identifying new adjuvants, and one strategy has
been to add back microbial factors that elicit strong immune responses to subunit formula-
tions. These factors are known as pathogen-associated molecular patterns (PAMPs) [12,13].
PAMPs are recognized as danger signals by pattern recognition receptors (PRRs) on the sur-
face of antigen presenting cells (APCs) [7]. PAMPs activate PRRs such as Toll-like receptors
(TLRs), which induce APCs to release cytokines and chemokines and to upregulate major
histocompatibility complex (MHC) class II and costimulatory molecules. Professional
APCs in turn prime T helper (Th) cells, which activate B cells to undergo class switching
and produce antigen-specific antibodies. Furthermore, the fusion of PAMPs to antigens has
been shown to significantly enhance antibody response compared to simply mixing the two
together [10,14,15]. The reason for this is that conjugation of adjuvant to antigen ensures
co-delivery to the same APC [16], which promotes optimal MHC class II presentation of
the antigen and strong stimulation of Th cell responses [10,17]. An example of a natural
antigen–adjuvant conjugate is a bacterial lipoprotein such as Factor H binding protein,
which constitutes the meningococcal Trumenba vaccine developed by Pfizer.
Bacterial lipoproteins are characterised by their leader peptide, which ends in a
lipobox with a conserved terminal cysteine [18]. A diacyl glyceryl group is conjugated
to the thiol side-chain of cysteine through a thioether linkage, then the signal peptide
is cleaved immediately prior to this cysteine (Figure 1A). In all Gram-negative bacteria
and in certain Gram-positive bacteria, a third fatty acid is attached to this N-terminal
cysteine through an amide linkage, generating a triacylated lipoprotein [19,20]. The lipid
moiety anchors the lipoprotein to the membrane, orientating its protein component out-
wards from its N-terminus [20–22]. The lipid domain of lipoproteins is a PAMP which
is recognised by TLR2 [23–26]. Examples of lipid moieties of bacterial lipoproteins that
have been studied for their adjuvant activity are dipalmitoyl-S-glycerol cysteine, Pam2Cys
(a synthetic version of the lipid moiety from macrophage-activating lipopeptide-2 derived
from Mycoplasma fermentans, Figure 1A) and tripalmitoyl-S-glycerol cysteine, Pam3Cys,
(a synthetic analogue of Brauns’ lipoprotein found in Gram-negative cell walls) [27–30].
Adjuvant is not the only requisite for vaccines to be effective. The route of immuni-
sation is an equally important factor to ensure targeting of the relevant body site. Ninety
percent of all infections occur in mucosal surfaces lining the gastrointestinal, respiratory
and urogenital tracts, where the first line of defense is secretory IgA (sIgA) [31]; however,
parenteral vaccines are largely limited to targeting pathogens that have already breached
the mucosal barrier, via serum IgG [32]. The limitations of the parenteral approach to
protect against non-invasive gut pathogens may partly explain the inability of Cdiffense
(Sanofi) intramuscular toxoid vaccine to protect against Clostridioides difficile infection,
which resulted in termination of its Phase III development. Mucosal vaccination, on the
other hand, can trigger humoural and cellular mediated immune protection not only at
mucosal sites, but also systemically [33].
For oral vaccines, potency is of paramount importance to overcome tolerance devel-
oped by the gut, which is constantly exposed to antigens; however, identifying effective
and safe oral adjuvants has been extremely challenging [3]. It is not surprising, then, that
all oral vaccines to date rely on the traditional whole cell approach (live attenuated or
inactivated), capitalising on the potency afforded by the presence of all the PAMPs of the
organism [3]. Only a handful of oral vaccines have been licensed, which collectively target
four infectious diseases: typhoid, cholera, rotavirus and polio. The historic issue around
their safety remains, and clearly a breakthrough is needed to develop safe subunit oral
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vaccine platforms with suitable adjuvants that can bypass degradation in the stomach
and reach the main mucosal inductive site of the distal small intestine, the gut-associated
lymphoid tissue (GALT) [34]. The bioavailability of oral vaccines is vital, as antigens
must be successfully taken up by M cells (specialised epithelial cells) and transcytosed
to underlying APCs in the Peyer’s patches of the GALT to stimulate protective immune
responses [34].
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Figure 1. Schematic diagrams of (A) attachment of native dipalmitoyl-S-glyceryl moiety to the N-
terminal cysteine of a bacterial lipoprotein antigen; (B) conjugation of synthetic lipid DHPPA-Mal 
to the N-terminal cysteine of a recombinant protein antigen. The acid–stable diether linkage is 
shown in a pink circle and the maleimide headgroup in a blue circle. Schematic diagrams of (C) a 
lipoprotein (shown in yellow) presented natively by a bacterial cell; and (D), a semi-synthetic lipo-
protein (shown in yellow) displayed on a liposome, generated by conjugation of the recombinant 
protein to DHPPA-Mal. C and D were created with GIMP GNU Image Manipulation Program (ver-
sion 2.10.22). 
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We recently reported that the colonisation factor CD0873 of C. difficile given orally
in enteric capsules to hamsters induced local and serum-neutralising antibody responses
which afforded partial protection against infection with a hypervirulent strain [35]. The
recombinant protein we tested resembles the mature, cleaved polypeptide of this lipopro-
tein, lacking lipid modification at the N-terminal cysteine. The limitations of the protein
on its own as an oral subunit vaccine, aside from its propensity for degradation, is in-
sufficient potency due to lack of adjuvant, as well as its tendency to form aggregates,
which can result in immunological epitopes escaping recognition by B cells. Furthermore,
soluble protein antigens are not as immunogenic as particulate antigens at mucosal sites,
which have greater propensity for M cell uptake and for APC targeting [36]. Moreover,
membrane-bound protein antigens are more effective at eliciting B cell responses than
soluble antigens [37–39].
With the above knowledge, the aim of this study was to test the hypothesis that
oral delivery of the whole protein antigen, CD0873, displayed on the outer membrane
of liposomal nanoparticles could stimulate enhanced antibody responses. A synthetic
lipid bearing features of Pam2Cys was designed for conjugation of the protein via its
N-terminal cysteine (Figure 1B) and to act as a linker for its surface display on liposomes.
In contrast to the acylated glycerol headgroup of Pam2Cys, whereby the lipids are linked
to the glycerol via ester bonds (Figure 1A), our lipid N-(2,3-bis(hexadecyloxy)propyl)-3-
(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamide (DHPPA-Mal) carries an alkylated
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amino-propanediol unit such that the lipids are linked via ether bonds for enhanced stability
in the gut (Figure 1B). A maleimide moiety is coupled to the amine of this subunit to enable
facile conjugation to the N-terminal cysteine (via a thioether bond) of the recombinant
antigen (Figure 1B).
Liposomes are phospholipid membrane vesicles with intrinsic adjuvant properties
that have attracted considerable interest as mucosal delivery systems [40]. Several studies
have shown that following oral administration, liposomes, like certain other nanoparticles,
are readily taken up by M cells [41,42]. We anticipated that the outer envelope of a
liposome, which resembles the phospholipid membrane of a bacterium, could be exploited
to present antigens “natively”. Specifically, the synthetic lipid could be formulated with
liposomal lipids and the whole protein antigen subsequently conjugated to headgroups
protruding from the outer envelope. This would allow orientation of the lipoprotein
outwards from the N-terminus, mimicking the native presentation of lipoproteins that are
anchored to the bacterial membrane (Figure 1C,D). The composition of liposomes (Lipo)
was based on the work of Han, who specifically optimised formulations for the gut [43].
Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylserine (DPPS) in
combination are effective at targeting liposomes to macrophages, DPPS is additionally
effective at inducing IgA, and cholesterol is included for stability [43–45]. DHPPA-Mal was
formulated with Lipo to create MalLipo.
To test whether whole proteins could be stably conjugated to MalLipo, recombinant
green fluorescent protein (GFP) was used as a test protein and all liposomal conjugations
were analysed by Fluorescence-Activated Cell Sorting (FACS). Once verified, recombinant
protein antigen CD0873 was conjugated to MalLipo to produce CD0873-MalLipo.
An immunogenicity study was conducted in hamsters to compare orally administered
CD0873-MalLipo with CD0873 for antibody titres in the small intestine and in sera as
well as for their respective neutralising properties. The Caco-2 cell line derived from
human colorectal adenocarcinoma cells was chosen for all adherence assays, as this is
the established intestinal epithelial model for C. difficile colonisation studies [46]. Our
data show that lipidated CD0873 displayed on liposomes induces a greater neutralising
antibody response than CD0873 given alone and causes no detectable immunopathology
in the gut. Our modular platform can be applied to other vaccines targeting the intestine,
for which finding suitable adjuvants has generally been the major bottleneck.
2. Materials and Methods
2.1. Bacterial Strains
Escherichia coli strains “NEB® 5-alpha competent E. coli” and “T7 Express competent
E. coli” were used for cloning purposes recombinant protein expression, respectively.
Both strains were purchased from New England Biolabs (NEB), Hitchin, UK. The strains
were cultured aerobically in Luria Bertani (LB) broth with shaking or on LB agar (Fisher
Bioreagents, Loughborough, UK) at 37 ◦C, unless stated otherwise. Where appropriate,
ampicillin was added to a final concentration of 100 µg/mL.
Clostridioides difficile strain 630 was kindly provided by Peter Mullany, UCL. Strain
630 is a virulent, multi-drug resistant strain isolated in 1985 from a hospital patient with
severe pseudomembranous colitis which spread to other patients on the same ward in
Zurich, Switzerland [47]. This outbreak strain harbours the two toxins TcdA and TcdB and
belongs to the PCR ribotype 012, and has now been adopted as the reference strain for
laboratory studies [48].
C. difficile strain 630 was cultured in Brain Heart Infusion medium (Oxoid) supple-
mented with 5 µg/mL yeast extract and 0.1% (w/v) L-cysteine (BHIS) containing selective
supplements, 250 µg/mL D-cycloserine and 8 µg/mL cefoxitin (Oxoid) (BHIS CC). The
strain was incubated overnight at 37 ◦C in an anaerobic workstation (Don Whitley Scientific,
Bingley, UK) with an atmosphere of CO2 (10%), H2 (10%) and N2 (80%).
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2.2. Chemical Reagents
Commercially available reagents and reagent-grade solvents were purchased from
Merck, Fluorochem or Fisher and used as received. Anhydrous solvents were purchased
from SigmaMerck Group, Feltam, UK, with the exception of Tetrahydrofuran (THF) and
dichloromethane (DCM), which were freshly distilled. All aqueous solutions were prepared
using deionised water. Dry solvents were used when indicated in the procedure. Glassware
was dried at 100 ◦C in a vacuum oven for 24 h.
2.3. Molecular Manipulations
Plasmid DNA was prepared using the Monarch® Plasmid Miniprep Kit according to
the manufacturer’s instructions (NEB). Enzymes for DNA manipulations included restric-
tion endonucleases (NEB), T4 DNA ligase (NEB) and Calf Intestinal Alkaline Phosphatase
(Invitrogen™, Thermo Fisher Scientific, Loughborough, UK). Gene cleaning was performed
using the Monarch® PCR and DNA Cleanup Kit (NEB) following the manufacturer’s in-
structions. DNA polymerase used for PCR for cloning purposes was Q5® High-Fidelity
DNA Polymerase (NEB), or Taq DNA polymerase (NEB) for verification of constructs.
PCRs were performed in an Eppendorf® Mastercycler® (Stevenage, UK). Reaction mixtures
were typically subjected to initial denaturation at 94 ◦C for 5 min followed by 35 cycles,
denaturation at 94 ◦C for 30 s, annealing at the appropriate temperature for the primers
for 30 s and extension at 72 ◦C for 30 s to 1 min depending on the length of amplicon,
followed by a final extension cycle at 72 ◦C for 5 min. The amplified DNA was visualised
by electrophoresis with 1% (w/v) agarose gels.
2.4. Cloning GFP Gene String into pTWIN1-His
Recombinant GFP was produced in the same manner as that described for recombinant
CD0873 [35]. Briefly, the Intein Mediated Purification with an Affinity Chitin-binding Tag-
Two Intein (IMPACT-TWIN) system was used (NEB), with our own modified pTWIN1-His
vector [35]. The nucleotide sequence of cysteine-free GFP [49] was codon-optimised for
E. coli, chemically synthesised (Life Technologies, Thermo Fisher Scientific), and then used
as template for PCR with primers GFP For: 5′-GTGGTTGCTCTTCCAACTGC-3′ and GFP
Rev: 5′-GGTGGTCTGCAGCTTGTACA-3′. The PCR products were digested with SapI and
PstI and ligated into the SapI-PstI sites of pTWIN1-His, and ligation mixtures were used
to transform NEB® 5-alpha cells. Clones were confirmed by sequencing and designated
pTWIN1-His-GFP, then transformed into T7 Express cells.
2.5. Expression and Purification of GFP by Immobilised Metal Affinity Chromatography (IMAC)
First, 1 L E. coli broth cultures A600 0.6–0.7 were induced by adding isopropyl β-D-
1-thiogalactopyranoside (IPTG) to a final concentration of 0.3 mM with shaking at room
temperature overnight. Cells were harvested by centrifugation. The cell pellet was resus-
pended in ice-cold binding buffer (20 mM Tris-HCl, 1 M NaCl, 40 mM imidazole, pH 7.4),
sonicated using the Fisherbrand™ Q500 Sonicator, then centrifuged. The supernatant
(cytosolic/soluble fraction) was harvested, the pellet (insoluble fraction) re-suspended in
binding buffer, and the fractions analysed by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE).
The soluble fraction was passed through a pre-charged Ni2+ PD-10 column (GE,
Healthcare Life Sciences, Amersham, UK) containing HisPur Ni-NTA Resin (Thermo Scien-
tific). The flow-through was collected, then the beads were washed with binding buffer to
remove unbound proteins. The target protein was eluted with increasing concentrations of
imidazole (50 mM, 100 mM, 250 mM and 500 mM) in elution buffer (0.1 M Tris-HCl and
2.5 M NaCl). All eluates were checked by SDS-PAGE, and those containing pure protein
were combined for dialysis in PBS at 4 ◦C overnight.
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2.6. Synthesis of Mal Lipid, N-(2,3-bis(hexadecyloxy)propyl)-3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-
1-yl) propanamide) Designated DHPPA-Mal (4)
2.6.1. (S)-2,3-bis(hexadecyloxy)propan-1-amine (3)
A solution of cetyl alcohol (5.0 g, 20.6 mmol) and Et3N (4.16 g, 41.1 mmol) in anhy-
drous DCM (100 mL) was cooled to 0 ◦C before mesyl chloride (2.84 g, 24.8 mmol) was
added dropwise. The solution was allowed to warm to room temperature and stirred for
16 h. After this time the reaction solution was diluted with DCM (100 mL) and washed
with 2 M HCl, 1 M NaHCO3, and brine. The organic extract was dried over MgSO4,
filtered and concentrated in vacuo. The resulting yellow solid was dried under high vac-
uum for 4 h, yielding pale yellow flakes (1, 6.34 g, 19.8 mmol, 96% yield). HRMS Calc.:
343.2283 [M + Na]+; Obs.: 343.2276 [M + Na]+. This product, (1), was taken on to the next
step without further purification.
A solution of (S)-3-amino-1,2-propanediol (0.23 g, 2.5 mmol) in anhydrous DCM:MeOH
(10:1, 25 mL) was stirred over Na2SO4 (1.78 g, 12.5 mmol) for 2 h before the drop-wise
addition of benzaldehyde (0.27 g, 2.5 mmol). The mixture was stirred at room temperature
for 24 h before filtration of the solid and concentration of the solution in vacuo. The resulting
oil (2) was dried under high vacuum for 6 h before being used directly. To an oven dried
and argon (Ar) flushed RB (round bottom) flask was added NaH (0.50 g, 12.5 mmol, 60%
dispersion in mineral oil, 5 equiv.). To this was added a solution of 2 (0.45 g, 2.5 mmol,
1 equiv.) in anhydrous THF (10 mL) under an Ar atmosphere. This mixture was stirred
at room temperature for 1 h before a solution of crude 1 (4.02 g, 12.6 mmol, 5 equiv.) in
anhydrous THF (10 mL) was added dropwise. Once added, the solution was heated to
reflux and left for 72 h under Ar. The reaction was quenched by the addition of water
(100 mL) and the aqueous layer extracted with DCM. The combined organic extracts were
washed with water, washed with brine, dried over MgSO4, filtered, and concentrated in
vacuo. The resulting oil was dissolved in DCM:TFA (1:1, 100 mL) and stirred at room
temperature for 16 h. Reaction progress was monitored by TLC. The reaction was concen-
trated in vacuo and the TFA co-evaporated with toluene. The resulting material was dried
under high vacuum to yield a brown oil, which was purified by column chromatography
(DCM to DCM:MeOH 8:2), yielding a brown solid (3, 0.57 g, 1.05 mmol, 42% yield). HRMS
Calc.: 540.5720 [M + H]+; Obs.: 540.5751 [M + H]+. 1H NMR (400 MHz, methanol-d4) δ
3.61–3.55 (m, 2H), 3.53–3.47 (m, 3H), 3.43 (t, J = 6.7 Hz, 2H), 3.08 (dd, J = 13.0, 4.3 Hz, 1H),
2.98 (dd, J = 13.1, 6.6 Hz, 1H), 1.59–1.55 (m, 4H), 1.31–1.25 (m, 52H), 0.88 (t, J = 6.8 Hz, 6H).
13C NMR (100 MHz, methanol-d4) δ 77.9, 77.6, 77.2, 70.3, 70.1, 69.8, 31.8, 29.7, 29.5, 29.5,
29.3, 29.2, 25.9, 25.9, 22.5, 13.6.
2.6.2. (S)-N-(2,3-bis(hexadecyloxy)propyl)-3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanamide (DHPPA-Mal) (4)
To a solution of 3-maleimidopropionic acid (45 mg, 0.27 mmol) in DMF (5 mL) was
added HATU (106 mg, 0.28 mmol) and DIPEA (71 mg, 0.55 mmol). This mixture was
stirred for 5 min before the addition of 3 (150 mg, 0.28 mmol). The solution was left to
stir for 24 h before being acidified with 1 M HCl, and the aqueous layer was extracted
with EtOAc. The combined organic layers were washed with water, washed with brine,
dried over MgSO4, filtered and concentrated in vacuo. The resulting oil was purified by
column chromatography (DCM to DCM:MeOH 9:1) and dried under high vacuum to yield
a brown solid (4, 50 mg, 0.072 mmol, 27% yield). HRMS Calc.: 690.6036 [M + H]+; Obs.:
691.5982 [M + H]+. 1H NMR (400 MHz, CDCl3) δ 6.69 (s, 2H), 5.96–5.94 (m, 1H), 3.84 (t,
J = 7.3 Hz, 2H), 3.59–3.38 (m, 8H), 3.30–3.24 (m, 1H), 2.50 (t, J = 7.3 Hz, 2H), 1.55 (m, 4H),
1.3–1.25 (m, 52H), 0.88 (t, J = 6.8 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 170.4, 169.5, 134.20,
77.3, 77.0, 76.7, 76.4, 71.9, 71.5, 70.2, 40.9, 34.6, 34.3, 31.9, 30.0, 29.7, 29.7, 29.5, 29.4, 26.1,
22.7, 14.1.
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2.7. Lipid Analysis
High-resolution mass spectra were recorded on a Bruker MicroTOF Focus II MS
(ESI) operating in positive or negative ionisation mode. NMR samples were analysed
on a Bruker AVIII 400 NMR system (1H-NMR frequency 400 MHz; 13C-NMR frequency
100 MHz). Chemical shifts are reported in parts per million (ppm) and are referenced to
solvent residual signals: CDCl3 (δ 7.26 [1H]). 1H NMR data is reported as chemical shift
(δ), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets,
ddd = doublet of doublet of doublets or combinations of these multiples; m = unassigned
multiplet), relative integral and coupling constant (J Hz).
2.8. Preparation of Liposomes
Liposomes were formulated with 3 µmol dipalmitoylglycerophosphoserine (DPPS)
(Avanti® Polar Lipids, Alabaster, AL, USA), 3 µmol dipalmitoylphosphatidylcholine
(DPPC) (Avanti® Polar Lipids, Alabaster, AL, USA) and 4 µmol cholesterol (Sigma Merck
Group, Feltam, UK) (total lipid concentration, 1 mM), and are referred to as “Lipo”. A simi-
lar suspension was made containing 2.5 µmol DPPS, 2.5 µmol DPPC and 4 µmol cholesterol
formulated with 1 µmol of DHPPA-Mal at a final concentration of 1 mM, and is referred to
as “MalLipo”. DPPC, DHPPA-Mal, and cholesterol were dissolved in chloroform and DPPS
in chloroform:methanol (1:1). Each lipid was dissolved to a concentration of 1 mM and the
lipids combined in the appropriate ratio. Each liposomal suspension was mixed thoroughly
in a 25 mL round bottom flask. The solvent was then evaporated using a Rotavapour®
R-114 (Büchi, Suffolk, UK) with the flask half-immersed in a Waterbath B480 (Büchi, Flawil,
Switzerland) at 40 ◦C. The resulting film layer of lipids was further dried under high
vacuum for 4 h. The film layer was resuspended in 10 mL PBS and sonicated on ice, using a
6 mm tip probe at 30% amplitude with 10 s on pulse and 30 s off pulse for a total of 30 min,
with the Fisherbrand™ Q500 Sonicator (500 W, 20kHz) (ThermoFisher Scientific, Walthem,
MA, USA). The resulting suspension of liposomes was analysed for Z-average particle size
and polydispersity index (PDI) by dynamic light scattering (DLS). DLS was performed
on a Malvern Zetasizer Nano-ZS; 1 mL of sample (formulation in PBS) was analysed
in a disposable cuvette at 25 ◦C. Standard parameters were applied: material refractive
index = 1.45; viscosity of PBS solution = 0.8872 cP; absorbance 0.100. Five measurements
were taken per sample, each involving fourteen scans at a 173◦ scattering angle.
2.9. Protein Conjugation of GFP to MalLipo
Since the liposomes were of the size range for multilamellar particles, it was estimated
that about 10–20% of the DHPPA-Mal formulated would protrude outwards, with the
remainder pointing inwards. GFP was used as a test protein for conjugation. The aim was
to saturate protruding DHPPA-Mal with an excess of GFP, which was tested by comparing
two molar equivalents: 2:1 and 5:1 of GFP to DHPPA-Mal in MalLipo. The MalLipo and
protein suspensions were concentrated to approximately 1.5 mL using Vivaspin 20 columns
with 50 kDa and 10 kDa cut-offs, respectively (GE Healthcare Life Sciences). Conjugations
were conducted in the presence of Tris-(2-carboxyethyl)phosphine (TCEP) (pH 7.5) at a
1:2 molar ratio of protein to TCEP. Incubations were performed with gentle shaking at
50 rpm overnight. Conjugates were purified by size exclusion chromatography (SEC)
to remove unbound GFP and excess TCEP. Briefly, SEC was performed using an ÄKTA
Pure Chromatography System with a Superdex 200 10/300 GL column (10 × 300 mm).
Column equilibration was performed for at least two column volumes in equilibration
solvent (filtered distilled water) and elution solvent (PBS) at a flow rate of 0.75 mL/min.
The wavelength detector was set to 280 nm and fractions were collected manually. Unicorn
7.0 software was used to record chromatograms.
The concentrations of GFP in all liposomal preparations were compared to the starting
concentration as assessed by a BCA assay. As a negative control for the conjugation, GFP
was incubated with Lipo. All formulations were compared by FACS analysis (2.10).
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To test if the integrity of GFP-MalLipo liposomes would be affected by lyophilisation
(a prerequisite for encapsulation in gelatin capsules), volumes of GFP-MalLipo containing
a total of 1 mg protein were mixed with 10× lipid mass of trehalose, snap-frozen in liquid
nitrogen, then freeze dried in a FreeZone 4.50 L,−84 ◦C Benchtop Freeze Dryer operating at
−78 ◦C with vacuum 0.125 mbar. The resulting powdered formulations were reconstituted
in PBS to the original volume and re-analysed by FACS.
2.10. FACS Analysis of GFP-MalLipo Formulations
FACS was conducted to evaluate conjugations of GFP to liposomes. The Astrios EQ
Cell sorter (Beckman Coulter-Life Sciences, Wycombe, UK) was used, and all outputs were
analysed using Kaluza Analysis 2.1 software (Beckman Coulter-Life Sciences, Wycombe,
UK). Liposomes and GFP were individually gated by their forward scatter (FSC) and side
scatter (SSC) using a 488 nm laser. For liposomes, both Lipo and MalLipo suspensions
were used for positive gating and for establishing GFP negative fluorescence. The me-
dian florescence (MFI) was used to determine the relative median fluorescence (rMFI) by
the equation:
rMFI =
MFI of liposomes in gated population
MFI of liposomes in negative control
2.11. Protein Conjugation of CD0873 to MalLipo, Lyophilisation and Capsule Packing
Conjugation of CD0873 to MalLipo was performed as described for GFP. The molar
ratio of CD0873 to DHPPA-Mal was 1:3.8; 13.9 mM (total lipid concentration) was incubated
with 20 mg of CD0873, with two equivalents of TCEP over protein. Following purification
via SEC in PBS, 13 mg of CD0873 was successfully conjugated onto MalLipo, as verified by
a BCA assay. Appropriate volumes of CD0873-MalLipo containing a total of 1 mg protein
were aliquoted and lyophilised as described for GFP (2.9). Each powdered aliquot was
packed separately into gelatin capsules, size 9 (Torpac Fairfield, NJ, USA) using the funnel,
tamper and stand provided by the manufacturer. Capsules were dip-coated once in enteric
polymer: 12.5% EUDRAGIT L100 (Evonik Industries, Essen, Germany) in isopropanol,
with Triethyl citrate (TEC) (10% w/v) and H2O (3% v/v) added, as previously described [35].
2.12. In Vivo Immunogenicity Study
Female Golden Syrian hamsters aged 12–16 weeks, weighing approximately 150 g
were purchased from Janvier Labs and housed in individually ventilated cages. Hamsters
were randomly divided into four groups: Experimental groups were either given capsules
containing CD0873 in excipient (n = 4) or CD0873-MalLipo in excipient (n = 4). Negative
control groups were either given nothing (naïve) or capsules containing excipient only
(n = 4). The purpose of this latter group was to check whether the capsule or excipient
contributed towards any immunogenicity detected in experimental groups. Oral dosing
with capsules was performed on days 1, 15 and 30. Hamsters were euthanised 14 days
post-final immunisation. Blood was collected by cardiac puncture, left to clot overnight at
4 ◦C, and serum harvested after centrifugation and then stored at −80 ◦C. A 5 mm section
of the ileum was taken for histological analysis (2.13). The remainder of the small intestine
was placed in 5 mL PBS containing SIGMAFAST™ protease inhibitors (Sigma Merck Group,
Feltam, UK), flushed through twice with this suspension, and the supernatant collected
after centrifugation. Intestinal fluid was filter-sterilised and stored at −80 ◦C.
2.13. Histopathological Assessment of Cecum
Sections of the small intestine were fixed in 10% (v/v) neutral buffered formalin (NBF)
(Sigma Merck Group, Feltam, UK) and then processed overnight on a 14 h programme
in a TP1020 Automatic Benchtop Tissue Processor (Leica Biosystems, Newcastle, UK).
Processed tissue was paraffin-embedded in a Histostar Embedding Workstation (Thermo
Fisher Scientific) and sectioned at 5 µm, then mounted on glass slides and Hematoxylin and
Eosin (H&E) stained (Leica ST 5020). Blinded analysis was conducted by an experienced
Vaccines 2021, 9, 1453 9 of 25
pathologist using an established scoring system. Sections were assessed for oedema (0–3),
neutrophil infiltration (0–3) and epithelial tissue damage (0–3), with 0 normal and 3 severe.
2.14. Western Immunoblotting
Procedures were performed with 5% (w/v) dry-milk (Sigma Merck Group, Feltam, UK)
in Tris buffered saline containing 0.01% (v/v) Tween (TBST) for blocking. All antibodies
were diluted in 1% (w/v) dry-milk in TBST, and TBST was used for washes. Samples were
added to 2X Lammeli sample buffer and fractionated by 10% (w/v) SDS-PAGE. Transfer
to PVDF membranes was conducted using the Trans-Blot Turbo Transfer System (Bio-
Rad Laboratories, Watford, UK). For confirmation of recombinant proteins, the primary
antibodies used were rabbit anti-His tag antibody (1:1000) (Cell Signaling Technology, CST,
Danvers, MA, USA), mouse anti-GFP antibody (1:5000) (Roche diagnostics, Mannheim,
Germany) and rabbit anti-CD0873 antibody (1:5000). Corresponding secondary antibodies
were anti-rabbit IgG horseradish peroxidase (HRP) (1:1000) (CST) and anti-mouse IgG HRP
(1:1000) (CST). Binding was detected by chemiluminescent ECL substrate and visualised
using the LICOR Odyssey Fc (LICOR Biosciences, Cambridge, UK).
For detection of mucosal IgA in intestinal fluids, rabbit anti-hamster secondary anti-
body (Brookwood Biomedical, Jemison, Birmingham, AL, USA) was used which specifically
detects IgA heavy chain (H). Briefly, anti-hamster IgA (H) antibody was purified from
rabbit anti-hamster IgM, IgG, IgA (H) by cross absorption against hamster IgG and IgM
(Brookwood Biomedical, Jemison, Birmingham, AL, USA) and used at 1:1000. Detection of
bound antibody was achieved by incubation of the membrane with anti-rabbit IgG HRP an-
tibody (1:1000) (CST) followed by 3,3′, 5,5′-Tetramethylbenzidine (TMB) substrate (Sigma
Merck Group, Feltam, UK), and bands were visualised using the Gel Doc™ XR system
(Bio-Rad, Hercules, CA, USA). Band intensity was quantified using ImageJ calibrated to
perform optical density based on a pallet of colours in grayscale [50].
2.15. Indirect ELISA to Assess IgG Levels in Serum
Ninety-six-well Nunc MaxiSorp™ plates (Thermo Fisher Scientific, Loughborough,
UK) were coated with 100 µL purified recombinant protein, CD0873, at a concentration
of 2.5 µg/mL in 0.2 M sodium bicarbonate, pH 9.4 and the proteins left to adsorb onto
the wells overnight at 4 ◦C. All wash stages consisted of five washes with 200 µL PBS
containing 0.01% (v/v) Tween (PBST). Wells were first blocked with 200 µL of 5% (w/v)
dry-milk (Sigma Merck Group, Feltam, UK) in PBST for 2 h at room temperature, washed
and then incubated over night at 4 ◦C after addition of 100 µL serum diluted 1:10 in PBST,
in triplicate. Wells were washed, then incubated for 2 h at room temperature in 100 µL
goat anti-hamster IgG highly cross-adsorbed Biotin antibody (Sigma Merck Group, Feltam,
UK) diluted 1:20,000 in PBST, washed again, then incubated for 2 h in Streptavidin-HRP
(R&D Systems, Minneapolis, MN, USA) diluted 1:200 in PBST. A650 was measured after
addition of 100 µL TMB substrate (Sigma Merck Group, Feltam, UK) for 15 min using the
CLARIOstar Plus (BMG Labtech) Plate Reader.
2.16. Adherence Blocking Assay to Measure Neutralising Ability of Vaccine-Induced Antibodies
Caco-2 cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM) (Thermo
Fisher Scientific, Loughborough, UK) supplemented with 4.5 g/L D-glucose, 584 mg/L
L-glutamine, 25 mM HEPES, 10% (v/v) FBS and penicillin/streptomycin in a humidified
5% CO2 atmosphere at 37 ◦C. Cells were seeded at 5 × 104 cells per well in 24-well tissue
culture plates (Corning, Flintshire, UK). Monolayers were used 14 days after seeding, with
medium changed every 2–3 days. The culture medium was further changed 24 h prior to
conducting the assay. The inoculum was prepared by standardising the optical density
(OD) of a 10 mL overnight broth culture of C. difficile strain 630 to A600 0.6, centrifuging and
washing the cells with PBS, and re-suspending the pellet in non-supplemented DMEM.
Caco-2 monolayers were infected at a multiplicity of infection (MOI) of 1:5 for intestinal
fluid samples and 1:20 for serum samples, in triplicate. To confirm the MOIs, serial
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dilutions of the cell suspension in PBS were plated on BHIS CC for enumeration of CFUs.
The adherence assay was performed under anaerobic conditions at 37 ◦C; 50 µL of serum
or intestinal fluid diluted 1:5 and 1:2, respectively, in non-supplemented DMEM were
added to 50 µL of the bacterial cell suspension and incubated for 1 h. This mixture was
then added to Caco-2 cells in triplicate following removal of the medium in the wells.
After 2 h of incubation, non-adherent bacteria were removed by pipetting and adherent
bacteria harvested as follows. Caco-2 cells were washed three times with PBS, incubated
in 200 µL 1X Trypsin-EDTA to detach them from the wells, then re-suspended in 300 µL
supplemented DMEM. The following day, 10−1 to 10−3 dilutions of cells in PBS were plated
on BHIS CC plates and CFU enumerated.
2.17. Statement
Animal studies were devised using the Experimental Design Assistant (EDA) online
tool and conducted in strict accordance with the requirements of the Animals Scientific
Procedure Act 1986. Prior approval for these procedures was granted by the University of
Nottingham Animal Welfare and Ethical Review Body and by the UK Home Office under
project license PPL P4712E8BB. Animals were euthanised by CO2 inhalation followed by
cervical dislocation in order to minimize suffering.
2.18. Statistical Analysis
The data were analysed by Kruskal–Wallis test followed by Dunn’s multiple compari-
son. Error bars represent the standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001.
All statistical tests were performed using GraphPad version 7 (San Diego, CA, USA);
p values of less than 0.05 were considered to indicate statistical significance.
3. Results
The aim of this study was to test the hypothesis that oral delivery of a whole protein,
CD0873, on liposomes resembling the bacterial membrane could induce a more effective
antibody response than CD0873 alone. A synthetic lipid, DHPPA-Mal (Figure 1B), bearing
features of the potent adjuvant Pam2Cys was designed for conjugation to the unique N-
terminal cysteine of the recombinant protein. To mimic native display, DHPPA-Mal was
first formulated with liposomal lipids, and CD0873 was then conjugated to maleimide
headgroups of this lipid protruding from the outer envelope of liposomes, mimicking the
same orientation of lipoproteins as on bacterial cells (Figure 1C,D). To test the assembly
of our nanoparticles, GFP bearing a unique N-terminal cysteine was used as a surrogate
antigen. FACS was conducted to directly compare the fluorescence of GFP liposomes
formulated with and without DHPPA-Mal.
3.1. Purification of Recombinant GFP with an N-Terminal Cysteine
The pTWIN1-His expression system was deployed to produce recombinant GFP with
a unique N-terminal cysteine, as described previously for CD0873 [35]. When cloning into
pTWIN1-His, the codon for cysteine is incorporated immediately after the SapI cloning site
in the forward primer, followed by the initial codons of the gene of interest. Following pH
or temperature-mediated cleavage of the upstream intein tag, the cysteine forms the new
N-terminus of the recombinant protein. A gene string was designed based on a previously
modified GFP gene with two cysteine substitutions (C48S and C70M) that proved to be
brighter and more photo-stable than standard GFP [49]. The nucleotide sequence of the
cysteine-free gene was codon-optimised for E. coli, chemically synthesised and then cloned
into the SapI-PstI sites of pTWIN1-His.
Following IPTG induction, the soluble fraction was applied to a Ni2+ column and
GFP eluted with imidazole. A band of expected size for GFP (29 kDa) was obtained, as
well as for previously purified CD0873 [35] and the two proteins confirmed by Western
immunoblotting (Figure 2).
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Figure 2. Purification of recombinant GFP (A) and confirmation of GFP and CD0873 by Western immunoblotting (B). (A) 
Detection of an intense band corresponding to the molecular weight of GFP in the induced soluble fraction of E. coli T7 
harbouring pTWIN1-His-GFP and in the eluate following purification of this fraction by IMAC, shown by the red arrow. 
Proteins were separated by SDS-PAGE (10% acrylamide) and stained with Coomassie Blue. NEB Colour Prestained pro-
tein ladder (lane M). (B) Coomassie-stained gel and Western immunoblots of recombinant GFP and CD0873 probed with 
anti-His tag antibody, anti-GFP antibody or anti-CD0873 antibody and detected by the addition of the appropriate HRP-
conjugated secondary antibody and chemiluminescent ECL substrate. Lane M: NEB Colour Pre-stained protein standard. 
Bands of expected molecular weight for CD0873 and GFP were detected as indicated by the arrows. 
  
Figure 2. Purificatio of recombina t GFP (A) and confirmation of GFP and CD0873 by Western
immunoblotting (B). (A) Detection of an intense band corresponding to the molecular weight of GFP
in the induced soluble fraction of E. coli T7 harbouring pTWIN1-His-GFP and in the eluate following
purification of this fraction by IMAC, shown by the red arrow. Proteins were separated by SDS-PAGE
(10% acrylamide) and stained with Coomassie Blue. NEB Colour Prestained protein ladder (lane M).
(B) Coomassie-stained gel and Western immunoblots of recombinant GFP and CD0873 probed with
anti-His tag antibody, anti-GFP antibody or anti-CD0873 antibody and detected by the addition of
the appropriate HRP-conjugated secondary antibody and chemiluminescent ECL substrate. Lane M:
NEB Colour Pre-stained protein standard. Bands of expected molecular weight for CD0873 and GFP
were detected as indicated by the arrows.
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3.2. Synthesis of DHPPA-Mal
The bespoke lipid DHPPA-Mal (4) was synthesized as shown in Scheme 1. Briefly,
the amine of (S)-3-amino-1,2-propanediol was protected as an imine using benzaldehyde
(2), before alkylation with mesylated cetyl alcohol (1) using NaH as the base. Hydrolysis
of the imine under acidic conditions afforded amine 3 in 43% yield over two steps after
purification via flash column chromatography. Then, 3-maleimidopropionic acid was
coupled to the free amine of 3 using HATU as the coupling agent to afford DHPPA-Mal (4)
in 34% yield after purification. NMR and MS data were consistent with the structure of
compound 4 (DHPPA-Mal) (Figures A1–A3).
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and 1 µmol DHPPA-Mal in a total volume of 10 mL PBS to create a 1 mM suspension 
(Figure 3). By thorough sonication, nanoparticles of 100–200 nm in diameter could be 
formed, which are of suitable size for uptake by M cells [41]. Analysis of the nanoparticles 
by DLS revealed that the Z-average particle size was 140 nm and the polydispersity index 
(PDI) was 0.20-0.26 (Figure A4). Lipo (liposomes lacking DHPPA-Mal) was formulated 
with 3 µmol DPPC, 3 µmol DPPS and 4 µmol cholesterol to yield a suspension of 1 mM 
in 10 mL. 
Scheme 1. Synthesis of DHPPA-Mal (4); schematic created in ChemDraw.
3.3. Formulation of Liposomes with DHPPA-Mal to Create MalLipo
Han and coworkers (1997) previ u ly demonstrated t at liposomes formulated with
DPPC, DPPS and cholesterol (1:1:2 molar ratio) showed stability in acidic solution (pH2),
bile and pancreatin solution, and were effective as an oral delivery vehicle for inducing
mucosal immune responses to the ncased antigen, in mice. With the need to include
DHPPA-Mal to create MalLipo formulations, the ratio of lipids was adjusted accordingly
and liposomes were formulated with 2.5 µmol DPPC, 2.5 µmol DPPS, 4 µmol cholesterol
and 1 µmol DHPPA-Mal in a total volume of 10 mL PBS to create a 1 mM uspension
(Figure 3). By thorough sonication, nanoparticles of 100–200 nm in diameter could be
formed, which are of suitable size for uptake by M cells [41]. Analysis of the nanoparticles
by DLS revealed that the Z-average particle size was 140 nm and the polydispersity index
(PDI) was 0.20–0.26 (Figure A4). Lipo (liposomes lacking DHPPA-Mal) was formulated
with 3 µmol DPPC, 3 µmol DPPS and 4 µmol cholesterol to yield a suspension of 1 mM in
10 mL.
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Lipo alone. Positive gating for liposomes was conducted on the Lipo and MalLipo suspen-
sions (Figure 4A,B) which also served as negative gating for GFP fluorescence. GFP was
positively gated on a GFP suspension (Figure 4C). All three suspensions showed an rMFI
of 1 (Figure 4A–C). GFP incubated with Lipo, (GFP-Lipo) had an rMFI of 1.7 (Figure 4D),
suggesting some GFP bound to liposomes electrostatically. GFP-MalLipo suspensions
generated from a 2:1 and 5:1 molar ratio of GFP to DHPPA-Mal (Figure 4E,F) gave a
13-fold and 19-fold increase in the rMFI relative to GFP-Lipo with values of 21.5 and 32.5,
respectively. The data show that GFP conjugated successfully to liposomes formulated
with DHPPA-Mal.
In order to administer liposomal formulations orally, the selected commercial gelatin
capsules require packing with dry powder formulations [35]. Thus, to test whether liposo-
mal formulations could be lyophilised and reconstituted without affecting the structural
integrity of the conjugated liposomes, aliquots of GFP-MalLipo suspensions, each contain-
ing a total of 1 mg of GFP, were lyophilised in a 10X lipid mass of trehalose as excipient and
then reconstituted in PBS to the original volume and reanalysed. No significant change
in the fluorescence profile, particle size or PDI were observed, confirming the stability of
the conjugates.
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analysed by comparing formulations generated from a 2:1 molar ratio (E) and 5:1 molar ratio (F) of GFP to MalLipo.
3.5. Conjugation of CD0873 to Liposomes
The same c jugation procedure was applied for recombinant CD0873; 20.0 mg of
CD0873 was mixed with 13.9 mM MalLipo in TCEP in a total volume of 1.55 mL. Following
purification via SEC, 13 mg of CD0873 were successfully conjugated onto M Lipo and
v rified by BCA assay. The nanoparticles were further analyse by DLS and di played a
Z- verage size of 111 nm and a PDI of 0.32 (Figure A5). Appropriate volumes of CD0873-
MalLipo containing a tot l of 1 mg protein were mixed with a 10X lipid mass of trehalose
and lyophilised. The powdered formulation was packed in Torpac capsules and the
capsules dip-coated once in enteric polymer, as previously described [35], before oral
administration to hamsters.
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3.6. Induction of Mucosal IgA and Serum IgG in Hamsters Orally Immunised with CD0873
and CD0873-MalLipo
Hamsters were dosed orally, one capsule per dose, on days 1, 15, and 30, then eu-
thanised two weeks later. One experimental group was immunised with capsules con-
taining 1 mg of CD0873, and another group with capsules containing CD0873-MalLipo
constituting 1 mg of CD0873. Negative control groups included naïve hamsters, and ham-
sters given capsules containing only excipient in order to verify that the capsule and/or
trehalose had no effect. At the experimental endpoint, a section of the ileum was taken for
histological analysis, and serum and intestinal fluid were harvested. Histological analysis
revealed no oedema or increase in neutrophil infiltration or damage to the epithelium in
any of the vaccinated hamsters, indicating good safety of the liposomal vaccine [35].
To investigate the prevalence of mucosal IgA in the small intestine, the diluted intesti-
nal fluid of each hamster was probed by Western immunoblotting with rabbit anti-hamster
IgA antibody and detected by anti-rabbit IgG HRP. An immuno-reactive band of the
expected size [51] was observed for all hamsters vaccinated with either CD0873 or CD0873-
MalLipo, unlike for the negative control groups. The intensity of each band was quantified
using ImageJ and the results plotted for each group as a histogram. IgA abundance was
greatest for the CD0873-MalLipo group, with p = 0.039 compared to the naïve group
(Figure 5A). As with naïve animals, since only a background level of antibody was de-
tected for the animals given capsules containing excipient only, this group was excluded
from further analysis.




Figure 5. Immune responses in hamsters immunised orally with CD0873 alone and CD0873-MalLipo. Intestinal fluid and 
serum were harvested from vaccinated hamsters and from negative control hamsters and tested for the presence of mu-
cosal IgA and serum IgG, respectively. Intestinal fluid was extracted by flushing the small intestine with 5 mL of PBS 
containing protease inhibitors, and serum was taken by cardiac puncture. (A) Intestinal fluid (5 µL) from each hamster 
was first fractionated by SDS-PAGE and transferred to a PVDF membrane then probed with rabbit anti-hamster IgA an-
tibody (1:1000). Bands were detected with anti-rabbit IgG HRP (1:1000) and TMB substrate, and band intensity was quan-
tified using ImageJ. (B) Serum diluted 1:10 of CD0873- and CD0873-MalLipo-vaccinated group and naïve group tested for 
IgG by indirect ELISA. Goat anti-hamster IgG highly cross-adsorbed Biotin antibody (1:20,000) and Streptavidin-HRP 
(1:200) were used for detection. Data were obtained from two independent experiments, each with three technical repli-
cates. Error bars represent standard error of the mean (SEM). All data were analysed by Kruskal–Wallis test followed by 
Dunn’s multiple comparison. Error bars represent the standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001. 
In order to test whether immunised hamsters generated a further systemic immune 
response, sera from immunised and naïve hamsters were compared by indirect ELISA. 
Wells were first coated in recombinant CD0873, then incubated in diluted serum. Biotin-
labelled goat anti-hamster IgG was added, and Streptavidin-HRP was used for detection. 
Sera of both vaccinated groups contained significant levels of antigen-specific IgG com-
pared to naïve animals: p = 0.0005 and p = 0.0065 for CD0873 and CD0873-MalLipo, re-
spectively, with a 1.6-fold greater level for CD0873 compared to CD0873-MalLipo, p > 
0.9999 (Figure 5B). 
3.7. Induction of Greater Neutralising Antibody Responses by CD0873-MalLipo Compared to 
CD0873 
To compare CD0873 and CD0873-MalLipo induced antibodies in terms of their neu-
tralising properties, Caco-2 cells were infected with C. difficile strain 630 pre-incubated 
with intestinal fluid diluted 1:2 or sera diluted 1:5 from each animal. Two hours post-
infection, cells were washed and detached from wells with Trypsin, serially diluted, 
plated, and the CFUs enumerated. 
The intestinal fluid from both groups blocked adherence of cells of C. difficile to Caco-
2 cells, with a significant reduction in adherence observed for the CD0873-MalLipo group 
compared to the naïve group (p = 0.0045), which was 1.9-fold greater than that observed 
for the CD0873 group (Figure 6A). The findings on the intestinal responses were mirrored 
Figure 5. Immune responses in hamsters immunised orally with CD0873 alone and CD0873-MalLipo.
Intestinal fluid and serum were harvested from vaccinated hamsters and from negative control
hamsters and tested for the presence of mucosal IgA and serum IgG, respectively. Intestinal fluid was
extr cted by flushing the sm ll intestine with 5 L of PBS containing protease inhibitors, and serum
was taken by cardiac puncture. (A) Intestinal fluid (5 µL) from each hamster was first fractionated by
SDS-PAGE and transferred to a PVDF membrane then probed with rabbit an i-h mster IgA antibody
(1:1000). Bands were detected with anti-rabbit IgG HRP (1:1000) and TMB substrate, and band
intensity was quantified using ImageJ. (B) Serum diluted 1:10 of CD0873- and CD0873-MalLipo-
vaccinated group and naïve group tested for IgG by indirect ELISA. Goat anti-ha ster IgG highly
cross-adsorbed Biotin antibody (1:20,000) and Streptavidin-HRP (1:200) were used for detection. Data
were obtained from two independent experiments, each with three technical replicates. Error bars
represent standard erro of the mean (SEM). All data were an lys d by Kruskal–Wallis test followed
by Dunn’s multiple comparison. Error bars represent the standard error of the mean. * p < 0.05,
** p < 0.01, *** p < 0.001.
In order to test whether immunised hamsters generated a further syste ic immune re-
sponse, sera from immunised and naïve hamsters were compared by indirect ELISA. Wells
were first coated in recombinant CD0873, then incubated in iluted serum. Biotin-labelled
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goat anti-hamster IgG was added, and Streptavidin-HRP was used for detection. Sera
of both vaccinated groups contained significant levels of antigen-specific IgG compared
to naïve animals: p = 0.0005 and p = 0.0065 for CD0873 and CD0873-MalLipo, respec-
tively, with a 1.6-fold greater level for CD0873 compared to CD0873-MalLipo, p > 0.9999
(Figure 5B).
3.7. Induction of Greater Neutralising Antibody Responses by CD0873-MalLipo Compared
to CD0873
To compare CD0873 and CD0873-MalLipo induced antibodies in terms of their neu-
tralising properties, Caco-2 cells were infected with C. difficile strain 630 pre-incubated with
intestinal fluid diluted 1:2 or sera diluted 1:5 from each animal. Two hours post-infection,
cells were washed and detached from wells with Trypsin, serially diluted, plated, and the
CFUs enumerated.
The intestinal fluid from both groups blocked adherence of cells of C. difficile to Caco-2
cells, with a significant reduction in adherence observed for the CD0873-MalLipo group
compared to the naïve group (p = 0.0045), which was 1.9-fold greater than that observed for
the CD0873 group (Figure 6A). The findings on the intestinal responses were mirrored by
responses in sera. The sera of both groups significantly blocked adhesion, CD0873-MalLipo
p = 0.0002 and CD0873 p = 0.0017, with the CD0873-MalLipo group exhibiting a 1.4-fold
greater reduction in adherence than the CD0873 group (Figure 6B). Thus, despite the lower
titre of IgG in the serum of the CD0873-MalLipo group (Figure 5B), the neutralising activity
was again more marked for this group than for the CD0873 group.
Vaccines 2021, 9, x  18 of 27 
 
 
by responses in sera. The sera of both groups significantly blocked adhesion, CD0873-
MalLipo p = 0.0002 and 0873 p = 0.0017, with the CD0873-MalLipo group exhibiting a 
1.4-fold greater reduction in adherence than the CD0873 group (Figure 6B). Thus, despite 
the lower titre of IgG in the serum of the CD0873-MalLipo group (Figure 5B), the neutral-
ising activity was again more marked for this group than for the CD0873 group. 
 
Figure 6. CD0873-MalLipo induces an elevated neutralising antibody response against Clostridioides difficile strain 630 
compared to CD0873. (A) Ability of intestinal wash (diluted 1:2) of vaccinated animals to block the binding of C. difficile 
cells to Caco-2 cells. A significant reduction in binding was seen for the group vaccinated with CD0873-MalLipo compared 
to the naïve group. (B) The adherence blocking assay with serum diluted 1:5. A significant reduction in the binding of cells 
of C. difficile to Caco-2 cells was observed for both groups, suggesting effective epitope recognition by serum antibodies. 
Three technical replicates were performed. The data were analysed by Kruskal–Wallis test followed by Dunn’s multiple 
comparison. Error bars represent the standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001. 
To conclude, our data show that the presentation of whole protein antigen CD0873 
on liposomes via conjugation with the DHPPA-Mal lipid to mimic native display of this 
lipoprotein on bacterial cells is more effective at inducing neutralising antibodies in the 
small intestine and bloodstream of hamsters than the recombinant antigen given alone. 
4. Discussion 
Mucosal vaccines have the potential to induce robust protective sIgA responses at 
the site of infection, preventing the initial establishment of disease as well as providing 
systemic IgG responses as a second line of defence. For protein-based vaccines, T-depend-
ent B cell activation is required. The B cell receptor (BCR) must recognise its cognate anti-
gen, and recognition is most effective if the antigen is encountered in its native form and 
is also membrane-bound [37–39]. In our study, we set out to test our oral protein antigen 
CD0873 [35] in this manner. Figure 7 illustrates the pathway from the initial transcytosis 
of antigen to the GALT, to recognition of the antigen by Follicular Th cells (CD4+ T cells) 
first on APCs and then on B cells, through to B cell activation, resulting in the secretion of 
antigen-specific sIgA. 
Figure 6. CD0873-MalLipo induces an elevated neutralising antibody response against Clostridioides
difficile strain 630 compared to CD0873. (A) Ability of intestinal wash (diluted 1:2) of vaccinated
animals to block the binding of C. difficile cells to Caco-2 cells. A significant reduction in binding was
seen for the r up vaccinat d with CD0873-MalLipo compared to the aïve gr up. (B) The adherence
blocking assay with serum diluted 1:5. A significant reduction in the binding of cells of C. difficile
to Caco-2 cells was obs rved for both groups, suggesting effective e itope recognition by serum
antibodies. Three technical replicates were performed. The data were analysed by Kruskal–Wallis
test followed by Dunn’s multiple comparison. Error bars represent the standard error of the mean.
* p < 0.05, ** p < 0.01, *** p < 0.001.
To conclude, our data show that the presentation of whole protein antigen CD0873
on liposomes via conjugation with the DHPPA-Mal lipid to mimic native display of this
lipoprotein on bacterial cells s m re eff c ive at inducing neutralising antibodies in the
small intestine and bloodstream of hamsters than the recombinant antigen given alone.
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4. Discussion
Mucosal vaccines have the potential to induce robust protective sIgA responses at the
site of infection, preventing the initial establishment of disease as well as providing systemic
IgG responses as a second line of defence. For protein-based vaccines, T-dependent B
cell activation is required. The B cell receptor (BCR) must recognise its cognate antigen,
and recognition is most effective if the antigen is encountered in its native form and is
also membrane-bound [37–39]. In our study, we set out to test our oral protein antigen
CD0873 [35] in this manner. Figure 7 illustrates the pathway from the initial transcytosis
of antigen to the GALT, to recognition of the antigen by Follicular Th cells (CD4+ T cells)
first on APCs and then on B cells, through to B cell activation, resulting in the secretion of
antigen-specific sIgA.




Figure 7. Production of antigen-specific sIgA in the intestine by T-dependent B cell activation. (1) Antigen is taken up by 
M cells and (2) delivered to APCs such as dendritic cells (DCs). (3) These professional APCs present peptide/MHC com-
plexes to naïve CD4+ T cells, activating those which express the T cell receptor (TCR) thatrecognises this peptide/MHC 
complex. Meanwhile, a mature naïve B cell recognises the native antigen by its BCR and processes and presents peptides 
of this antigen via MHC class II, along with the co-stimulatory receptor CD40. One of the peptides presented by the B cell 
is recognised by the previously-primed CD4+ T cell. The interaction of B and T cells via MHC-class II/TCR and 
CD40/CD40L, as well as by receptors with cytokines, induces strong activation of B cells. (4) Activated B cells proliferate 
and differentiate into sIgA+ B cells, which migrate to the mesenteric lymph nodes and circulate in the bloodstream before 
homing in to the intestinal Lamina propria to become mature. (5) The resident IgA+ plasma cells release dimeric or poly-
meric IgA, which forms a complex with the polymeric Ig receptor on the basolateral side of epithelial cells; the complex is 
transcytosed and released as sIgA at effector sites. (6). This figure was created with BioRender.com. 
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Figure 7. Production of antigen-specific sIgA in the intestine by T-dependent B cell activation. (1) Antigen is taken up
by M cells and (2) delivered to APCs such as dendritic cells (DCs). (3) These professional APCs present peptide/MHC
complexes to naïve CD4+ T cells, activating those which express the T cell receptor (TCR) thatrecognises this peptide/MHC
complex. Meanwhile, a mature naïve B cell recognises the native antigen by its BCR and processes and presents peptides of
this antigen via MHC class II, along with the co-stimulatory receptor CD40. One of the peptides presented by the B cell is
recognised by the previously-primed CD4+ T cell. The interaction of B and T cells via MHC-class II/TCR and CD40/CD40L,
as well as by receptors with cytokines, induces strong activation of B cells. (4) Activated B cells proliferate and differentiate
into sIgA+ B cells, which migrate to the mesenteric lymph nodes and circulate in the bloodstream before homing in to the
intestinal Lamina propria to become mature. (5) The resident IgA+ plasma cells release dimeric or polymeric IgA, which
forms a complex with the polym ric Ig receptor on the basolat ral side of epithelial cells; the complex is transcytosed and
released as sIgA at effector sites. (6). This figure was created with BioRender.com.
Delivering whole protein resembling intact native a tigen to the Peyer’s patches of
the ileum is a major challenge. To overcome degradation in the stomach, we previously
demonstrat d the succ ss of ente ic capsules rgeting the small intestine of hamsters [35].
Our n xt strategy was to use robust, gut- ptimised liposomes [43] t display membrane-
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bound antigen and deliver the antigen whole to the GALT. Traditionally, liposomes are
deployed to display peptides as opposed to proteins [52]; however, this restricts the
number of epitopes of the protein that can be presented and compromises their structural
conformation, which can impact upon immune recognition. Our liposomes, which included
cholesterol for solidity [43], provided the necessary structural support for whole proteins
to remain stably conjugated, as demonstrated by the use of GFP. The composition of our
liposomes was based on the formulation previously shown by Han, et al. (1997) [43]
to be stable in gastro-intestinal fluids. The robustness of our liposomes likely afforded
some protection of the antigen from degradation, enabling epitopes to be preserved. The
individual conjugation of each CD0873 molecule to the synthetic lipid formulated with
the liposomes would additionally serve to minimise protein aggregation, which can mask
epitopes and affect recognition of naïve B cells by the BCR.
Other benefits of our liposomal platform likely include improved uptake by M cells,
as the lipid particles were of suitable size for uptake [41]. The combination of DPPC and
DPPS in liposomes may have aided macrophage targeting following transcytosis. The
enhanced biological activity of CD0873-MalLipo may be partly attributed to the liposomal
lipid DPPS, which is known to have IgA-inducing properties [32], and to the synthetic lipid
linker, which may have directly enhanced the immunogenicity of the attached antigen.
Pam2Cys consists of two palmitoyl fatty acid C16 chains adjoined to a glyceryl-
cysteine motif by ester linkages (Figure 1A). Length-wise, C16 chains are optimal for
activating cells through TLR2, while shorter chains induce no or little activity [53]. The ester
linkages are also important for activating TLR2 [53]. However, synthesis of lipoproteins
carrying this native scaffold is challenging, and therefore analogues that are easier to
synthesise have been investigated instead for their immunostimulatory potential [53].
Important in the design of our vaccine platform targeting the intestine was the need for
hydrolytic stability of the lipid and its facile conjugation to whole antigen. Retaining the
core glyceryl (2,3-dihydroxypropyl) headgroup of Pam2Cys with native stereochemistry,
which is substantially more active than the alternative (S)-diastereomer found in some
analogues, we installed C16 chains via hydrolytically stable ether linkages. To enable
effective bioconjugation of the antigen, we installed a maleimide moiety via a propanimidyl
linker (Figure 1B). Facile conjugation of whole protein molecules to the outer envelope of
MalLipo particles could then be performed under mild conditions between the N-terminal
cysteine of the protein and protruding maleimide headgroups (Figures 1D and 3B).
Our future work will be to deploy Pam2Cys itself, which is likely to be far more
potent than DHPPA-Mal and is superior to other lipid PAMPs that have been tested.
Moyle et al (2014) compared Pam2Cys along with other lipids conjugated via Expressed
Protein Ligation (EPL) to a recombinant polypeptide comprising multiple antigens of
Group A Streptococcus [29]. Following subcutaneous administration in mice, the Pam2Cys
vaccine yielded the highest titre of IgG specific for multiple epitopes, with broader cross-
reactivity to a diverse panel of strains than the other micelle formulations tested. Even
though our lipid did not harbour all the important features of Pam2Cys, it is possible that
CD0873-MalLipo generated antibodies with broader epitope recognition than CD0873 that
enhanced their binding to CD0873 exposed on the surface of cells of C. difficile. Supporting
the findings of Kovacs-Simon et al. (2014) [54] we previously showed that CD0873 is indeed
abundant on the surface of cells of C. difficile 630 [35], the strain used in this study. Pam2Cys
is not only a potent immunostimulatory adjuvant in parenteral vaccines, it has shown
encouraging efficacy in mucosal vaccines, including in an intra-nasal vaccine [28] and in
an oral vaccine [55]. In addition to utilising Pam2Cys, we plan to conjugate additional
antigens to our liposomal platform, such as immunological domains of the two toxins of
C. difficile, and to test this multivalent vaccine for its protective efficacy against C. difficile
infection in the hamster lethality model.
To summarise, mucosal vaccines negate the need for needles, reducing cost and
potentially leading to increased compliance and reduced risk of transmissible diseases
spreading, as has been experienced with the spread of hepatitis C and HIV following
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the use of injected vaccines [32]. Furthermore, as strongly reinforced by the COVID-19
pandemic, there is an urgent need for vaccines that can be stored at room temperature and
easily distributed globally without the need for refrigeration. Oral vaccines are attracting
great interest since they can induce systemic immune responses as well as local and distal
mucosal responses, and thus potentially target most body sites. When administered orally
in enteric capsules for targeting the small intestine, we show our liposome platform is
an effective delivery system for whole-protein antigens, enhancing their immunogenicity.
We show that our liposomal formulations can be lyophilised and stored stably at room
temperature and reconstituted in vivo to induce mucosal and systemic antibody responses
without causing any detectable immunopathology. We believe our safe subunit approach
could be a preferred oral platform over the current whole cell approach, which remains
unsuitable for the elderly or immunocompromised.
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